Healthcare Sector

ELDN

Market Tracker

$3.95
-0.08
(-1.99%)
10:40 am
Next Earnings: (est.) 08/12/23 12:00 am
  • ELDN (Selected)

    Eledon Pharmaceuticals, Inc.

ELDN Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

ELDN Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

ELDN Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

ELDN Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

ELDN Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

ELDN Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
08/15/2025 CALL $7.50 10 +5 +100.00%
01/17/2025 CALL $2.50 0 0
01/17/2025 CALL $5.00 44 0
01/17/2025 CALL $7.50 0 0
01/17/2025 CALL $10.00 0 0
01/17/2025 PUT $2.50 220 0
05/16/2025 PUT $10.00 2 0
08/15/2025 CALL $2.50 34 0
08/15/2025 CALL $5.00 20 0
08/15/2025 PUT $2.50 0 0
08/15/2025 PUT $5.00 5 0
08/15/2025 PUT $7.50 0 0

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

ELDN Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 3.34% 460k 634.8k
Vanguard Extended Market Index Fund 1.46% 201.26k 277.74k
Fidelity Extended Market Index Fund 0.55% 75.45k 104.12k
iShares Micro Cap ETF 0.17% 22.83k 31.51k
Fidelity Total Market Index Fund 0.13% 18.47k 25.48k
Fidelity Series Total Market Index Fund 0.12% 16.81k 23.2k
Vanguard Institutional Index-Inst Total Stock Market Ind 0.10% 13.26k 18.3k
Fidelity NASDAQ Composite Index Fund 0.08% 10.48k 14.46k
DFA U.S. Core Equity 2 Portfolio 0.04% 5.08k 7.01k
DFA U.S. Vector Equity Portfolio 0.03% 4.11k 5.67k

ELDN News

  • 4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com

    07/24 08:36 am

    Investing.com

    Read more
  • Are Medical Stocks Lagging DaVita (DVA) This Year?

    06/26 09:40 am

    Zacks Investment Research

    Read more
  • Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

    06/03 04:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

    05/27 09:55 am

    Zacks Investment Research

    Read more
  • Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?

    05/22 12:00 pm

    Zacks Investment Research

    Read more
  • Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade

    05/14 12:00 pm

    Zacks Investment Research

    Read more
  • Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

    05/09 07:30 am

    GlobeNewswire Inc.

    Read more
  • Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence

    05/07 03:40 pm

    Benzinga

    Read more
  • Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

    05/07 07:05 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

    03/28 04:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

    03/25 04:56 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

    03/21 10:31 am

    GlobeNewswire Inc.

    Read more
  • Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    02/13 08:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

    01/04 05:40 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    12/04 07:00 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

    11/29 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Expert Ratings for Eledon Pharma

    11/13 11:00 am

    Benzinga

    Read more
  • Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

    11/09 05:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

    11/09 10:55 am

    Zacks Investment Research

    Read more
  • Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

    11/08 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

    11/02 09:05 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

    10/23 07:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

    10/13 07:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

    10/02 07:00 am

    GlobeNewswire Inc.

    Read more
  • Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023

    09/27 11:00 am

    Benzinga

    Read more
  • Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

    09/25 07:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

    09/20 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

    09/11 07:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

    06/02 08:00 am

    GlobeNewswire Inc.

    Read more
  • Why Chewy Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

    06/01 07:55 am

    Benzinga

    Read more
  • Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

    03/31 06:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

    03/30 04:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

    03/23 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

    02/08 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Provides Business and Pipeline Updates

    01/09 09:31 am

    GlobeNewswire Inc.

    Read more
  • C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

    12/21 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

    11/03 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS

    10/24 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

    09/22 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

    08/01 05:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    06/10 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Penny Stocks To Buy Now? 4 To Watch This Week

    05/31 09:49 am

    PennyStocks

    Read more
  • Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

    05/31 06:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

    05/05 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

    04/18 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

    04/14 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

    03/24 04:01 pm

    GlobeNewswire Inc.

    Read more
  • The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

    03/24 08:10 am

    Benzinga

    Read more
  • Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

    02/08 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

    12/27 06:17 pm

    GlobeNewswire Inc.

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: